A detailed history of Ronald Blue Trust, Inc. transactions in Novavax Inc stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 50 shares of NVAX stock, worth $450. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50
Previous 109 54.13%
Holding current value
$450
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

SELL
$10.71 - $17.11 $631 - $1,009
-59 Reduced 54.13%
50 $0
Q2 2024

Jul 18, 2024

BUY
$3.89 - $20.97 $229 - $1,237
59 Added 118.0%
109 $1,000
Q1 2024

May 01, 2024

SELL
$3.76 - $6.02 $97 - $156
-26 Reduced 34.21%
50 $0
Q4 2023

Jan 18, 2024

BUY
$4.8 - $7.67 $364 - $582
76 New
76 $0
Q1 2023

Apr 17, 2023

SELL
$5.76 - $12.48 $63 - $137
-11 Reduced 91.67%
1 $0
Q4 2022

Jan 17, 2023

SELL
$8.86 - $25.04 $53 - $150
-6 Reduced 33.33%
12 $0
Q3 2022

Oct 21, 2022

BUY
$18.2 - $76.12 $327 - $1,370
18 New
18 $1,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $704M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Ronald Blue Trust, Inc. Portfolio

Follow Ronald Blue Trust, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ronald Blue Trust, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ronald Blue Trust, Inc. with notifications on news.